Symbol="APVO"
AssetType="Common Stock"
Name="Aptevo Therapeutics Inc"
Description="Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington."
CIK="1671584"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="2401 4TH AVE., SUITE 1050, SEATTLE, WA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="7764500"
EBITDA="-29949000"
PERatio="0.294"
PEGRatio="0"
BookValue="3.212"
DividendPerShare="0"
DividendYield="0"
EPS="3.5"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.48"
ReturnOnEquityTTM="1.925"
RevenueTTM="0"
GrossProfitTTM="3114000"
DilutedEPSTTM="3.5"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-1"
AnalystTargetPrice="14.5"
TrailingPE="0.294"
ForwardPE="3.945"
PriceToSalesRatioTTM="1.607"
PriceToBookRatio="0.814"
EVToRevenue="0.122"
EVToEBITDA="-0.0345"
Beta="5.23"
num_52WeekHigh="4.67"
num_52WeekLow="0.76"
num_50DayMovingAverage="1.506"
num_200DayMovingAverage="2.142"
SharesOutstanding="7544200"
DividendDate="2020-03-27"
ExDividendDate="None"
symbol="APVO"
open="1.03"
high="1.05"
low="1.03"
price="1.04"
volume="50713.00"
latest_trading_day="2023-07-27"
previous_close="1.02"
change="0.02"
change_percent="1.9608%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="129982"
Change_recent_avg="-0.01"
Delta_recent_avg="0.12"
Variance_recent_avg="0.06"
Change_ratio_recent_avg="-0.96"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="508"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0097.jpeg"
image_negative_thumbnail_id_2="136"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0040.jpeg"
image_neutral_thumbnail_id_1="528"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0071.jpeg"
image_neutral_thumbnail_id_2="524"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0075.jpeg"
image_positive_thumbnail_id_1="954"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0116.jpeg"
image_positive_thumbnail_id_2="686"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0022.jpeg"
image_professor_thumbnail_id_1="1198"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
image_professor_thumbnail_id_2="1184"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
